$0.03
-0.01(-22.34%)
Mkt Cap $17.7K
$0.02
$0.10
52-Week Range
At a Glance
AI-generated8-K
Aclarion, Inc. adopted a stockholder rights agreement on March 19, 2026, declaring a dividend of one right per outstanding share of common stock and per Rights-Eligible Warrant to holders of record on March 30, 2026. The rights plan, with a one-year duration, aims to protect stockholders by requiring a control premium for any acquisition of 10% or more of common stock.$17.7K
Market Cap
—
Revenue
—
Net Income
Employees5
Fundamentals
How The Business Makes Money
Aclarion, Inc., a healthcare technology company, develops software application for magnetic resonance spectroscopy (MRS) in the United States. It offers NOCISCAN-LS Post-Processor suite comprising NOCICALC-LS that receives and processes the acquired disc MRS data to calculate levels of degenerative pain biomarkers; and NOCIGRAM-LS, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was founded in 2008 and is based in San Mateo, California.
Industry Medical - Healthcare Information Services
Activity
What Changed Recently
Company Profile
CIK0001635077
ISINUS6551871105
CUSIP655187110
Phone650-241-1741
Address951 Mariners Island Boulevard, Broomfield, CA, 94404, US
SEC EDGAR